DNAVEC obtains United States patent.
DNAVEC Research, Inc. (Ibaraki, Japan) has patented a recombinant Sendai virus vector for introducing exogenous genes to airway epithelia and a method for introducing exogenous genes using the vector. The recombinant Sendai virus vector enables efficient gene transfer to native mucus-layered airway epithelial cells by briefly contacting the vector with the cells. Furthermore, the vector can introduce genes to not only apical surfaces but also submucosal glands where CFTR primarily expresses. The vector can thus be used for gene therapy of CF, a CFTR-deficient disease. (US 7,314,614)
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Nov 1, 2007|
|Previous Article:||InterMune buys out license agreement for pirfenidone.|
|Next Article:||Innogenetics obtains United States patent.|